EP3272348A1 — Pharmaceutical composition comprising idelalisib
Assigned to Lek Pharmaceuticals dd · Expires 2018-01-24 · 8y expired
What this patent protects
The present invention relates to a new pharmaceutical composition comprising idelalisib, or a salt or a prodrug or a solvate thereof, and pharmaceutically acceptable excipients, said excipients providing efficient idelalisib release from final dosage form in gastric and post-gast…
USPTO Abstract
The present invention relates to a new pharmaceutical composition comprising idelalisib, or a salt or a prodrug or a solvate thereof, and pharmaceutically acceptable excipients, said excipients providing efficient idelalisib release from final dosage form in gastric and post-gastric conditions. The present invention relates to a new process for the preparation of pharmaceutical composition comprising idelalisib or a salt or a prodrug or a solvate thereof, or a salt, or a prodrug, or a solvate thereof. The pharmaceutical composition is particularly useful as a medicament, especially for the treatment of cancers of hematopoietic origin.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.